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The association between homozygous alpha,-antitrypsin
deficiency and chronic obstructive pulmonary disease was
first described by Laurell and Eriksson in 1963' and since
then numerous reports have confirmed and extended their
observations. The concept envisages a relatively uninhi-
bited proteolytic enzymatic proce.s which is able to pro-
duce type A (emphysematous), type B (chronic bronchitic)
or a mixed form of lung disease, depending on the site
of maximum effect.' The first 2 South African cases with
homozygous a!pha,-antitrypsin deficiency associated with
severe obstructive airways disease are described in this
paper together with studies of some members of their
respective families.
The procedure used for measuring alpha,-antitrypsin
deficiency was that of Eriksson' The normal range for
this laboratory is 1·0 - '·7 mg trypsin inhibited per ml
of serum. Levels between 0·3 mg and 1·0 mg were re-
garded as denoting heterozygosity while a figure less than
0·3 mg conferred homozygous status.
CASE REPORTS
Case 1
The patient's first symptoms occurred in 1956, at the
age of 27, when he noticed the presence of exertional
dyspnoea. There was no cough or sputum production at
this stage. During the next 6 years the dyspnoea worsened
and, in addition, physical signs of hyperinflation and
airway obstruction occurred. There was decreased cardiac
and liver dullness, poor diaphragmatic movement, de-
creased breath sounds and- expiratory rhonchi. In 1962 he
first developed a cough which became productive only
in 1966, by which time he was able to walk no more
than 50 yards. At this stage he had the physical features
of the type A (emphysemataus or 'pink puffer') form of
obstructive disease with severe obstruction, hyperinflation
and hyperventilation at rest: In addition, there was also
clinical pulmonary hypertension. Thereafter, he developed
progressive respiratory failure with cor pulmonale and
died in 1969. In the last year of his life he exhibited
marked paranoia.
His cigarette consumption was 20/ day for 20 years. As
a child he had suffered from pneumonia, measles, whoop-
ing cough and mumps. There was a strong family history
on his maternal side of lung disease, including pneumonia,
asthma, chronic bronchitis and emphysema. Unfortunately
none of these patients or their clinical records were
available to us.
Initial chest X-rays in 1960 were normal. By 1967,
however, there was marked flattening of the diaphragms
with very littie excursion, hypertranslucent lung fields,
marked prominence of the pulmonary artery segment with
attenuation of the peripheral vessels but no heart-chamber
enlargement (Fig. I). Later, during the Jast 18 months
of his life, some right-sided enlargement of the heart
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developed. Electrocardiographic examination in 1960
(Fig. 2) showed a mean QRS frontal plane axis of about
Fig. 1. Chest X-ray of case 1 taken in 1967.
!i
Fig. 2. Electrocardiograms of case I laken in 1960 and
1969.
90° and clockwise rotation. By 1969, there was very
marked right atrial and right ventricular enlargement.
Full blood count, urea and electrolyte investigations
were normal. His protein electrophoretic pattern showed
the following results: albumin 4·33 g/lOO ml, alpha,-
globulin 0·01 g/lOO ml, alpha,-globulin 0·53 g/lOO ml,
beta-globulin 0·99 g/IOO ml and gamma-globulin 0·84
g/ lOO ml. Investigation of the tryptic inhibitory capacity
of the serum showed 0·28 mg trypsin inhibited per ml
of serum, and therefore a homozygous state.
Lung function studies were performed on 5 occasions
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between 1960 and 1969 (Table I). Vital capacity dimi-
nished on successive testing while there was increasing
hyperinflation as represented by the rise in residual
volume. There was progressive airway obstruction and
arterial oxygen desaturation, the latter becoming more
marked on exercise. Despite the hypoxaemia, the Iow
arterial carbon dioxide tension demonstrates the alveolar
hyperventilation characteristic of the 'pink puffer'. He
eventually developed respiratory acidosis and died.
Specific studies of the tryptic inhibitory capacity of
the patient's 3 daughters showed that all were heterozy-
gotes. The figures measured in mg trypsin inhibited per
ml serum were J.L. 0'98; L.L. 0'81; and T.L. 0·89. There
was no clinical evidence of pulmonary disease in any of
them. The patient's wife had normal antitryptic activity.
Case 2
The patient first developed a cough productive of white
sputum in 1934 at 11 years of age. This cough persisted
with sputum production being at first intermittent and
later persistent, with occasional episodes of superimposed
infection. By the age of 30 he had noticed the onset of
exertional dyspnoea which was gradually progressive. He
smoked heavily from the age of 16 for 20 years. A
brother and a sister both had asthma. He was first seen
at Johannesburg Hospital in 1962 suffering from pneu-
monia. On examination he was obese, slightly cyanosed,
plethoric and showed evidence of cor pulmonale and
right heart failure. In the chest diffuse rhonchi, poor
breath sounds and hyperinflation were present. The hae-
moglobin was 18·7 g/lOO rnl with a packed cell volume
of 60%. Chest X-rays showed hypertranslucent lung fields
and flat, poorly moving diaphragms. The pulmonary
artery segment and central pulmonary vessels were promi-
nent but the heart was not enlarged. An electrocardio-
gram showed right atrial and right ventricular hypertro-
phy. Therapy with antibiotics, anti-failure drugs and
bronchodilators was instituted and maintained, but the
obstructive airways disease and cor pulmonale gradually
progressed and he died in 1970. The clinical impression
remained predominantly that of the type B or 'blue
bloater' form of obstructive airways disease.
A marked feature on his final admission was the
presence of diffuse bruising. Full coagulation and fibrino-
lytic studies were performed but no abnormality was
detected. Serum protein electrophoresis was performed
in 1969 and showed a total protein of 6·4 g/l00 ml with
an alpha,-globulin of 0'10 g/lOO ml. Serum antitryptic
activity was measured and showed 0'347 mg trypsin inhi-
bited/ml serum.
The patient's 5 children, who are well, and his wife
also had their serum antitryptic activity measured. The
figures measured in mg trypsin per ml serum were: Mr
D. B., age 23 years, 0·76; Miss S. B., age 19 years, 0'72
.Mr F. B., age 15 years, 0'64; Miss M. B., age 13 years,
0'88; and Miss L. B., age 10 years, 0·62. The patient's
wife had normal antitryptic activity of 1·24 mg but the
children are all heterozygotes. Despite the fact that the
patient's measured level was slightly above the accepted
figure for our laboratory it is highly probable that he
was a homozygote.
Lung function tests performed in 1965 showed very
severe obstructive airways disease with carbon dioxide
retention, the latter feature being commonly present in
the type B form of disease. Further tests performed in
1969 showed further carbon dioxide retention together
with a greatly increased residual volume and marked
arterial oxygen desaturation at rest (Table I).
DISCUSSION
The 2 homozygous patients described above have several
common features such as an early onset of symptoms,
death in early middle-age, strong family histories of pul-
monary disease and asymptomatic heterozygous children.
Equally important is the marked divergence in clinical
presentation inasmuch as case 1 presented predominantly
with type A (emphysematous) disease while case 2 tended
towards the clinical features of type B (bronchitic) in-
volvement. If the theory of alpha I-antitrypsin deficiency
is to be accepted it should explain both the common and
apparently divergent features of these 2 patients.
Normally about 90% of serum antitryptic activity cir-
culates as an alpha,-globulin and is called alpha,-anti-
TABLE I. LUNG FUNcnON STUDIES
Ca.se I Case 2
1960 1962 1966 1967 1969 1965 1969
Vital capacity litres measured .. 6'30 6·20 4-83 3·20 1'32 2'18 3·09
% of predicted value I11 108 85 58 24 43 62
Functional residual capacity litres measured 6·43 6-43 6·66 7-11 6·47
% of predicted value .. . . . . . . . . 151 151 158 169 156
Residual volume litres measured .. 3'n2 3·58 4·65 6·74 5·54
% of predicted value 170 165 206 291 242
Total lung capacity litres measured 992 9·78 H8 8·06 863
% of predicted value .. . . . . 126 123 121 102 118
MYYF htre/min me'lsured 98 96 44 35 8 22 24
% of predicted value .. 57 55 27 21 6 If> 18
FEV, litres 207 2·23 1·08 0·8 0·37 0·50 0·65
Rest ventilation litres/min 12·0 16·4 17·8 16·0 7·9 10-4
Arterial 0, saturation %-rest 90 91 82 80 88,5* 71·5
Arterial 0, saturation %-ex. 82 77 61 59
Blood pH 7-395 7-43 7-315 7·38 7-43
Blood peo, mmHg 30·5 290 49·0 48·5 89·0
*Patient was breathing O~ continuously and tolerated only 2 minutes without it, when this measurement was made.
Technique':) and predicted va~ues used have been pubiished previOl:sly.4-7
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trypsin. In some patients with chronic obstructive pulmo-
nary disease, a decrease in alpha I-antitryptic activity has
been found, the defect probably being carried via an
autosomal-recessive gene. Thus homozygous patients
having about 10% of normal activity, and heterozygotes,
having about 50% of the normal value, have been de-
scribed.·
Alpha,-antitrypsin or very similar globulins inhibit
several other proteolytic enzymes besides trypsin, such
as chymotrypsin, plasmin, thrombin9 and elastase,'· as well
as the digestive enzymes released from leucocytes." The
theory claims that deficiency of antitryptic activity per-
mits digestion of protein. Thus continual slow release of
poorly inhibited proteolytic enzymes from alveolar macro-
phages, leucocytes and other phagocytic cells may result
in digestion of alveolar septa producing panacinar em-
physema or type A disease. In those cases where there
is chronic bronchial irritation by agents such as cigarette
smoke, recurrent infections, or air pollution, the leuco-
cytic enzymes would be concentrated in the airways and
the lack of proteolytic inhibition could result in predomi-
nant chronic bronchitis and centrilobular emphysema
(type B disease).' Obviously a combination of the 2 types
of disease could occur.
It is possible that part of the bronchitic element in
case 2 could be ascribed to the patient's cigarette smoking,
but coughing had begun at the age of 11 years, 5 years
before he had started smoking. In Eriksson's series' about
half of his homozygous-deficient patients had evidence
of chronic bronchitis and chronic cough before the onset
of dyspnoea.
There appears to be a definite association between the
homozygous state and obstructive airways disease, especi-
ally panacinar emphysema, the incidence varying from
I to 100 0",,13 or more"·lG depending on the group of
patients studied. Whether heterozygotes have an increased
liability to disease is still disputed. Some authors have
not found this association,"'lS while others" have claimed
that heterozygous subjects do have an increased liability
to pulmonary involvement. Lieberman," in fact, found
that 15·2% of 66 patients hospitalized with pulmonary
emphysema had heterozygous alpha,-antitrypsin deficiency.
The over-all incidence of the deficiency was 25'8 % in
this group. Of patients under the age of 50 years, 47·8%
had deficient levels. If such observations are confirmed,
the role of alpha,-antitrypsin activity will assume a posi-
tion of great importance in this increasingly common
disease. It must be emphasized, however, that not all
people with the deficiency-even homozygotes-will de-
velop disease, and other factors must therefore be operable
as well.
The best and simplest screening test for alpha ,-anti-
trypsin deficiency is protein electrophoresis, preferably
performed by the cellulose acetate method.'• An alpha,-
globulin level of less than 0·20 g/lOO ml should be
followed by a more specific test for antitrypsin deficiency.
The most commonly used method is the enzymatic
measurement of the trypsin-inhibitory capacity of the
serum as performed in our cases described above. Alter-
native techniques such as immunodiffusion'" or antigen-
antibody-crossed electrophoresis" have also been de-
scribed. It should be noted that, especially in a heterozy-
gote, infection," pregnancy'" or contraceptive pills' may
raise the levels of alphaI-antitrypsin into the normal range.
Since antitryptic activity also functions against other
proteolytic enzymes, it was thought that increased fibrino-
lytic activity might be present, especially in the second
patient, who bruised very easily. However, full testing
failed to disclose any defect. Possibly, since there is a
large degree of functional reserve in antifibrinolytic acti-
vity, an additional situation involving increased fibrino-
lysis might bring out such a tendency.
SUMMARY
The first 2 cases of homozygous alpha,-antitrypsin deficiency
in South Africa are described, together with evidence demon-
stratina the heterozygous status of their children. Their clinical
course~ and special investigations are described illustrating
that these cases may present with either predominantly em-
physematous or bronchitic features. The condition is reviewed
and the methods and importance of diagnosis are pointed out.
We wish to thank the staff of the Pneumoconiosis Research
Unit for the estimations of trypsin inhibitory capacity, and
Dr M. Salmon, Medical Superintendent of Johannesburg
Hospital, for permission to publish.
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